---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016625"
form_type: "8-K"
ticker: "SYBX"
cik: "0001527599"
company_name: "SYNLOGIC, INC."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:47:56.429633+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Synlogic Q2 2022 net loss $15.8M; cash $106.8M funds into 2024; three data readouts in H2 2022

## Summary
- Net loss $15.8M ($0.22 per share) vs $14.5M ($0.28) in Q2 2021; revenue $0.2M from Roche IBD collaboration.
- Cash, equivalents, and short-term investments $106.8M as of June 30, 2022; projected runway into 2024.
- Plan to report Phase 2 PKU data in H2 2022 and start Phase 3 in H1 2023; HCU Phase 1 and EH proof-of-concept data also due H2 2022.
- Named SYNB2081 (uric acid-lowering Synthetic Biotic for gout), second candidate from Ginkgo Bioworks partnership.
- R&D expenses $12.1M (up from $10.7M) and G&A $4.1M (flat YoY).

## SEC filing metadata
- accession: 0000950170-22-016625
- form_type: 8-K
- ticker: SYBX
- cik: 0001527599
- company_name: SYNLOGIC, INC.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527599/000095017022016625/0000950170-22-016625-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527599/000095017022016625/sybx-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016625
- JSON: https://secwatch.observer/filing/0000950170-22-016625.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016625.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.